MXPA03007836A - Composiciones que tienen biodisponibilidad mejorada de eletriptano. - Google Patents

Composiciones que tienen biodisponibilidad mejorada de eletriptano.

Info

Publication number
MXPA03007836A
MXPA03007836A MXPA03007836A MXPA03007836A MXPA03007836A MX PA03007836 A MXPA03007836 A MX PA03007836A MX PA03007836 A MXPA03007836 A MX PA03007836A MX PA03007836 A MXPA03007836 A MX PA03007836A MX PA03007836 A MXPA03007836 A MX PA03007836A
Authority
MX
Mexico
Prior art keywords
compositions
improved bioavailability
bioavailability
improved
Prior art date
Application number
MXPA03007836A
Other languages
English (en)
Spanish (es)
Inventor
Michael John Humphrey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA03007836A publication Critical patent/MXPA03007836A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MXPA03007836A 2001-03-01 2002-02-20 Composiciones que tienen biodisponibilidad mejorada de eletriptano. MXPA03007836A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0105131.7A GB0105131D0 (en) 2001-03-01 2001-03-01 Compositions having improved bioavailability
PCT/IB2002/000512 WO2002070070A2 (en) 2001-03-01 2002-02-20 Compositions having improved bioavailability of eletriptan

Publications (1)

Publication Number Publication Date
MXPA03007836A true MXPA03007836A (es) 2003-12-08

Family

ID=9909814

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03007836A MXPA03007836A (es) 2001-03-01 2002-02-20 Composiciones que tienen biodisponibilidad mejorada de eletriptano.

Country Status (8)

Country Link
EP (1) EP1372785A2 (cg-RX-API-DMAC10.html)
JP (1) JP2004529893A (cg-RX-API-DMAC10.html)
AU (1) AU2002232061A1 (cg-RX-API-DMAC10.html)
BR (1) BR0207751A (cg-RX-API-DMAC10.html)
CA (1) CA2439917A1 (cg-RX-API-DMAC10.html)
GB (1) GB0105131D0 (cg-RX-API-DMAC10.html)
MX (1) MXPA03007836A (cg-RX-API-DMAC10.html)
WO (1) WO2002070070A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089365A1 (en) * 2003-04-11 2004-10-21 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9709739D0 (en) * 1997-05-14 1997-07-02 Merck Sharp & Dohme Pharmaceutical formulation
US6255334B1 (en) * 1998-10-30 2001-07-03 Pfizer Inc 5HT 1 receptor agonists and metoclopramide for the treatment of migraine

Also Published As

Publication number Publication date
WO2002070070A2 (en) 2002-09-12
GB0105131D0 (en) 2001-04-18
JP2004529893A (ja) 2004-09-30
EP1372785A2 (en) 2004-01-02
WO2002070070A3 (en) 2003-04-10
BR0207751A (pt) 2004-03-09
AU2002232061A1 (en) 2002-09-19
CA2439917A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
MXPA03009558A (es) Compuestos novedosos.
MXPA03007093A (es) Nueva composicion.
MXPA03008961A (es) Composicion de vacuna.
MXPA03008798A (es) Composiciones antibacterianas.
ZA200208561B (en) Hydraulischer druckverstarker.
ZA200308717B (en) Herbicidal composition.
MXPA01009037A (es) I-bet.
HUP0400174A2 (en) Lipid-polymer-conjugates compositions
ZA200302929B (en) Compositions comprising cyclohexamantane.
MXPA03009698A (es) Vacuna multivalente que comprende un antigeno vih y un antigeno vsh y/o un antigeno vph.
MXPA03007693A (es) Composicion para la piel.
MXPA03005286A (es) METODO Y APARATO PARA SUPERVISAR PULSACION DE INSTALACION DE ORDEnA.
MXPA03008140A (es) Amidas de acido benzofuran-2-carboxilico sustituidas.
MXPA03007539A (es) Composicion herbicida.
MXPA03008139A (es) Fluoralcoxifenilsulfonilureas sustituidas.
MXPA03009002A (es) 5-halogeno-6-fenil-7-fluoroalquilamino-triazolopirimidinas.
ZA200206779B (en) Solid formulation.
GB0200763D0 (en) Compositions
GB0105622D0 (en) Compositions
EG23378A (en) Composition.
ZA200306923B (en) Fungicide compositions.
EG23207A (en) Novel fungicidal compositions based on propamocarsand pyridylmethylbenzamide derivatives.
ZA200403323B (en) Anthelmintic composition.
MXPA03005994A (es) Compuestos de peptidos.
MXPA03008394A (es) Derivados de biuretano.